President Trump is expected to nominate Dr. Heidi Overton, currently deputy director of domestic policy at the White House, as commissioner of the Food and Drug Administration, according to people familiar with the decision.
Overton is a physician who joined the White House at the start of Trump's second term and has led health policy since. She has been at the center of the administration's most contested domestic priorities — redesigning the food pyramid, overhauling the childhood vaccine schedule, and negotiating drug pricing deals with pharmaceutical companies.
She has worked closely with the Department of Health and Human Services throughout her tenure. People familiar with her role describe her as one of the most influential health policy voices in the administration, with authority that extended well beyond the typical scope of a domestic policy deputy director.
Her relationship with leaders of the Make America Healthy Again movement has been complicated. According to people familiar with the matter, Overton has at times frustrated MAHA figures — a dynamic that adds political complexity to a nomination requiring Senate confirmation.
Overton will face scrutiny from a Senate panel focused on her stances toward the childhood vaccine schedule and the administration's approach to pharmaceutical companies, both flashpoints during Trump's second term.
The FDA has lacked stable leadership for months, marked by high-profile staff exits and pharmaceutical industry complaints. The agency has operated without a confirmed commissioner during that stretch.
If confirmed, Overton would inherit an agency responsible for regulating roughly 20 cents of every dollar spent by American consumers — covering prescription drugs, medical devices, food safety, and tobacco. The FDA's decisions determine which treatments reach patients, what appears on grocery store shelves, and how quickly new medicines advance through clinical review.
The childhood vaccine schedule represents one of her most politically charged files. The administration's effort to overhaul it has drawn criticism from public health organizations and support from MAHA-aligned groups, placing the FDA at the center of a conflict between the medical establishment and the administration's coalition.
Pharmaceutical pricing is the other major file. Overton's direct involvement in working out pricing arrangements between the administration and drug companies could shape how aggressively the FDA moves on drug approval timelines and industry negotiations under her leadership.
The food pyramid redesign effort she led at the White House reflects broader administration interest in reshaping federal nutrition guidance — guidance that affects school lunch programs, federal dietary recommendations, and food manufacturer labeling practices.
Overton's expected nomination represents a direct White House promotion: she moves from shaping policies the FDA executes to running the agency charged with executing them. That proximity to administration decision-making gives her a profile unlike most previous FDA commissioners, who typically came from academic medicine, the pharmaceutical industry, or the agency's own senior ranks.
